<DOC>
	<DOCNO>NCT01030432</DOCNO>
	<brief_summary>The purpose study identify one dose BMS-650032 , use combination pegylated-interferon alpha ribavirin safe demonstrate sufficient activity hepatitis C virus ( Genotypes 1 4 ) .</brief_summary>
	<brief_title>Study BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Subjects chronically infect HCV genotype 1 ( Phase 2a Phase 2b ) Subjects chronically infect HCV genotype 4 ( Phase 2b ) HCV RNA viral load ≥ 10*5* IU/mL screen BMI 18 35 kg/m² screen Cirrhosis ( Phase 2a ) Decompensated cirrhosis ( Phase 2b ) Coinfection HBV HIV Hepatocellular carcinoma Prior treatment antiHCV drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>